262 related articles for article (PubMed ID: 27072194)
1. Genomic aberrations frequently alter chromatin regulatory genes in chordoma.
Wang L; Zehir A; Nafa K; Zhou N; Berger MF; Casanova J; Sadowska J; Lu C; Allis CD; Gounder M; Chandhanayingyong C; Ladanyi M; Boland PJ; Hameed M
Genes Chromosomes Cancer; 2016 Jul; 55(7):591-600. PubMed ID: 27072194
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma.
Zhu GG; Ramirez D; Chen W; Lu C; Wang L; Frosina D; Jungbluth A; Ntiamoah P; Nafa K; Boland PJ; Hameed MR
Hum Pathol; 2020 Oct; 104():73-83. PubMed ID: 32795465
[TBL] [Abstract][Full Text] [Related]
3. Recurrent loss of chromosome 22 and SMARCB1 deletion in extra-axial chordoma: A clinicopathological and molecular analysis.
Wen X; Cimera R; Aryeequaye R; Abhinta M; Athanasian E; Healey J; Fabbri N; Boland P; Zhang Y; Hameed M
Genes Chromosomes Cancer; 2021 Dec; 60(12):796-807. PubMed ID: 34392582
[TBL] [Abstract][Full Text] [Related]
4. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
Kluzek K; Srebniak MI; Majer W; Ida A; Milecki T; Huminska K; van der Helm RM; Silesian A; Wrzesinski TM; Wojciechowicz J; Beverloo BH; Kwias Z; Bluyssen HAR; Wesoly J
Oncotarget; 2017 Apr; 8(17):28558-28574. PubMed ID: 28212566
[TBL] [Abstract][Full Text] [Related]
5. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
6. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
8. Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival.
Bai J; Shi J; Li C; Wang S; Zhang T; Hua X; Zhu B; Koka H; Wu HH; Song L; Wang D; Wang M; Zhou W; Ballew BJ; Zhu B; Hicks B; Mirabello L; Parry DM; Zhai Y; Li M; Du J; Wang J; Zhang S; Liu Q; Zhao P; Gui S; Goldstein AM; Zhang Y; Yang XR
Nat Commun; 2021 Feb; 12(1):757. PubMed ID: 33536423
[TBL] [Abstract][Full Text] [Related]
9. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
11. Recurrent chromosomal copy number alterations in sporadic chordomas.
Le LP; Nielsen GP; Rosenberg AE; Thomas D; Batten JM; Deshpande V; Schwab J; Duan Z; Xavier RJ; Hornicek FJ; Iafrate AJ
PLoS One; 2011; 6(5):e18846. PubMed ID: 21602918
[TBL] [Abstract][Full Text] [Related]
12. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.
Choy E; MacConaill LE; Cote GM; Le LP; Shen JK; Nielsen GP; Iafrate AJ; Garraway LA; Hornicek FJ; Duan Z
PLoS One; 2014; 9(7):e101283. PubMed ID: 24983247
[TBL] [Abstract][Full Text] [Related]
13. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T
Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
[TBL] [Abstract][Full Text] [Related]
15. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1.
Scheil S; Brüderlein S; Liehr T; Starke H; Herms J; Schulte M; Möller P
Genes Chromosomes Cancer; 2001 Nov; 32(3):203-11. PubMed ID: 11579460
[TBL] [Abstract][Full Text] [Related]
17. New candidate chromosomal regions for chordoma development.
Bayrakli F; Guney I; Kilic T; Ozek M; Pamir MN
Surg Neurol; 2007 Oct; 68(4):425-30; discussion 430. PubMed ID: 17714767
[TBL] [Abstract][Full Text] [Related]
18. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development.
Duns G; Hofstra RM; Sietzema JG; Hollema H; van Duivenbode I; Kuik A; Giezen C; Jan O; Bergsma JJ; Bijnen H; van der Vlies P; van den Berg E; Kok K
Hum Mutat; 2012 Jul; 33(7):1059-62. PubMed ID: 22461374
[TBL] [Abstract][Full Text] [Related]
19. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
20. Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation.
Hallor KH; Staaf J; Jönsson G; Heidenblad M; Vult von Steyern F; Bauer HC; Ijszenga M; Hogendoorn PC; Mandahl N; Szuhai K; Mertens F
Br J Cancer; 2008 Jan; 98(2):434-42. PubMed ID: 18071362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
